Skip to Content
You are currently on the new version of our website. Access the old version .

1,349 Results Found

  • Review
  • Open Access
13 Citations
5,687 Views
12 Pages

Cardiotoxicity and Chemotherapy—The Role of Precision Medicine

  • Thyla Viswanathan,
  • Chim C. Lang,
  • Russell D. Petty and
  • Mark A. Baxter

8 December 2021

Cancer and cardiovascular disease are the leading causes of death in the United Kingdom. Many systemic anticancer treatments are associated with short- and long-term cardiotoxicity. With improving cancer survival and an ageing population, identifying...

(This article belongs to the Section Cardiology)
  • Review
  • Open Access
6 Citations
4,335 Views
23 Pages

Cardiotoxicity in Elderly Breast Cancer Patients

  • Kalliopi Keramida,
  • Anastasia Constantinidou,
  • Dorothea Tsekoura,
  • Effrosyni Kampouroglou and ,
  • Chrissovalantis Aidarinis,
  • Emmanouil Saloustros,
  • Georgia Karanasiou,
  • Gaia Giulia Angela Sacco,
  • Erika Matos and
  • Investigators CARDIOCARE Consortium
  • + 13 authors+ 8 authors

30 June 2025

Cardiotoxicity is a leading cause of mortality in the growing populations of elderly breast cancer (BC) patients. Breast cancer treatment in the elderly is highly challenging due to its heterogeneous nature and the lack of specific evidence, as this...

(This article belongs to the Section Cancer Survivorship and Quality of Life)
  • Review
  • Open Access
24 Citations
9,268 Views
19 Pages

31 October 2023

The study of mechanisms underlying cardiotoxicity of doxorubicin and the development of strategies to mitigate doxorubicin-induced cardiotoxicity are the most relevant issues of modern cardio-oncology. This is due to the high prevalence of cancer in...

(This article belongs to the Section Pharmaceutical Science)
  • Review
  • Open Access
48 Citations
8,354 Views
23 Pages

Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics

  • Archana Adhikari,
  • Syed Mohammed Basheeruddin Asdaq,
  • Maitham A. Al Hawaj,
  • Manodeep Chakraborty and ,
  • Gayatri Thapa,
  • Nihar Ranjan Bhuyan,
  • Mohd. Imran,
  • Mohammed Kanan Alshammari,
  • Mohammed M. Alshehri and
  • Nagaraja Sreeharsha
  • + 8 authors+ 3 authors

25 September 2021

The advancement in therapy has provided a dramatic improvement in the rate of recovery among cancer patients. However, this improved survival is also associated with enhanced risks for cardiovascular manifestations, including hypertension, arrhythmia...

(This article belongs to the Special Issue Cancer Drugs Treatment and Toxicity)
  • Review
  • Open Access
35 Citations
6,061 Views
24 Pages

MicroRNAs in Cancer Treatment-Induced Cardiotoxicity

  • Laura Pellegrini,
  • Sara Sileno,
  • Marco D’Agostino,
  • Eleonora Foglio and ,
  • Maria Cristina Florio,
  • Vincenzo Guzzanti,
  • Matteo Antonio Russo,
  • Federica Limana and
  • Alessandra Magenta
  • + 4 authors+ 0 author

17 March 2020

Cancer treatment has made significant progress in the cure of different types of tumors. Nevertheless, its clinical use is limited by unwanted cardiotoxicity. Aside from the conventional chemotherapy approaches, even the most newly developed, i.e., m...

(This article belongs to the Collection Targeting Solid Tumors)
  • Review
  • Open Access
26 Citations
4,903 Views
15 Pages

ICIs-Related Cardiotoxicity in Different Types of Cancer

  • Mei Dong,
  • Ting Yu,
  • Zhenzhen Zhang,
  • Jing Zhang and ,
  • Rujian Wang,
  • Gary Tse,
  • Tong Liu and
  • Lin Zhong
  • + 3 authors+ 0 author

Immune checkpoint inhibitors (ICIs) are rapidly developing immunotherapy cancer drugs that have prolonged patient survival. However, ICIs-related cardiotoxicity has been recognized as a rare, but fatal, consequence. Although there has been extensive...

  • Article
  • Open Access
33 Citations
7,376 Views
22 Pages

Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine

  • Irwin K. Cheah,
  • Richard M. Y. Tang,
  • Xiaoyuan Wang,
  • Karishma Sachaphibulkij and ,
  • Suet Yen Chong,
  • Lina H. K. Lim,
  • Jiong-Wei Wang and
  • Barry Halliwell
  • + 3 authors+ 0 author

30 January 2023

Background: Anthracyclines such as doxorubicin remain a primary treatment for hematological malignancies and breast cancers. However, cardiotoxicity induced by anthracyclines, possibly leading to heart failure, severely limits their application. The...

(This article belongs to the Section Health Outcomes of Antioxidants and Oxidative Stress)
  • Review
  • Open Access
232 Citations
19,011 Views
28 Pages

Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity

  • Bin Bin Wu,
  • Kam Tong Leung and
  • Ellen Ngar-Yun Poon

9 February 2022

Anthracyclines, such as doxorubicin, are effective chemotherapeutic agents for the treatment of cancer, but their clinical use is associated with severe and potentially life-threatening cardiotoxicity. Despite decades of research, treatment options r...

(This article belongs to the Special Issue Metabolic Therapies for Heart Failure)
  • Article
  • Open Access
67 Citations
7,453 Views
22 Pages

Immune Checkpoint Inhibitors—Associated Cardiotoxicity

  • Chenghui Li,
  • Sajjad A. Bhatti and
  • Jun Ying

23 February 2022

Large population-based studies examining differences in ICI-associated cardiotoxicity across cancer types and agents are limited. Data of 5518 cancer patients who received at least one cycle of ICIs were extracted from a large network of health care...

  • Review
  • Open Access
13 Citations
4,397 Views
13 Pages

Cardiotoxicity Associated with Chemotherapy Used in Gastrointestinal Tumours

  • Liliana Maria Radulescu,
  • Dan Radulescu,
  • Tudor-Eliade Ciuleanu,
  • Dana Crisan and ,
  • Elena Buzdugan,
  • Dragos-Mihai Romitan and
  • Anca Dana Buzoianu
  • + 2 authors+ 0 author

6 August 2021

Cardiotoxicity is a well-recognised side effect of cancer-related therapies with a great impact on outcomes and quality of life in the cancer survivor population. The pathogenesis of chemotherapy-induced cardiotoxicity in patients with gastrointestin...

(This article belongs to the Section Cardiology)
  • Review
  • Open Access
10 Citations
3,248 Views
8 Pages

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors

  • Inbar Nardi Agmon,
  • Osnat Itzhaki Ben Zadok and
  • Ran Kornowski

7 February 2022

The use of immune checkpoint inhibitors (ICIs) as a mono- or adjuvant oncologic treatment is rapidly expanding to most fields of cancer. Alongside their efficacy, ICIs carry the risk of immune-related adverse events (irAEs) arising from misguided imm...

(This article belongs to the Special Issue Cardio-Oncology: Diagnosis and Management of Cardiovascular Disease in Cancer Patients)
  • Review
  • Open Access
6 Citations
4,871 Views
35 Pages

Role of GPCR Signaling in Anthracycline-Induced Cardiotoxicity

  • Nimish Biswal,
  • Ritika Harish,
  • Minahil Roshan,
  • Sathvik Samudrala and ,
  • Xuanmao Jiao,
  • Richard G. Pestell and
  • Anthony W. Ashton
  • + 2 authors+ 0 author

22 January 2025

Anthracyclines are a class of chemotherapeutics commonly used to treat a range of cancers. Despite success in improving cancer survival rates, anthracyclines have dose-limiting cardiotoxicity that prevents more widespread clinical utility. Currently,...

(This article belongs to the Section Cell Signaling)
  • Review
  • Open Access
42 Citations
8,863 Views
23 Pages

Cardiotoxicity of Fluoropyrimidines: Epidemiology, Mechanisms, Diagnosis, and Management

  • Michał Jurczyk,
  • Magdalena Król,
  • Aleksandra Midro,
  • Magdalena Kurnik-Łucka and ,
  • Adrian Poniatowski and
  • Krzysztof Gil
  • + 1 author+ 0 author

27 September 2021

Cancer is a growing public health problem; it is responsible annually for millions of deaths worldwide. Fluoropyrimidines are highly effective and commonly prescribed anti-neoplastic drugs used in a wide range of chemotherapy regimens against several...

(This article belongs to the Special Issue Prevention and Management of Chemotherapy-Induced Side Effects in Survivors of Adult Cancers)
  • Review
  • Open Access
13 Citations
7,329 Views
22 Pages

Cardiotoxicity of Chemotherapy: A Multi-OMIC Perspective

  • Yan Ma,
  • Mandy O. J. Grootaert and
  • Raj N. Sewduth

Chemotherapy-induced cardiotoxicity is a critical issue in cardio-oncology, as cancer treatments often lead to severe cardiovascular complications. Approximately 10% of cancer patients succumb to cardiovascular problems, with lung cancer patients fre...

  • Article
  • Open Access
9 Citations
2,930 Views
14 Pages

Hyperhomocysteinaemia Promotes Doxorubicin-Induced Cardiotoxicity in Mice

  • Rui Fan,
  • Yao Wang,
  • Jinjin Zhang,
  • Xiangbo An and ,
  • Shuang Liu,
  • Jie Bai,
  • Jiatian Li,
  • Qiuyue Lin,
  • Yunpeng Xie and
  • Yunlong Xia
  • + 6 authors+ 1 author

28 August 2023

Doxorubicin, a widely used chemotherapeutic drug in clinical oncology, causes a series of cardiac side effects referred to as doxorubicin-induced cardiotoxicity. Hyperhomocysteinaemia is an independent risk factor for multiple cardiovascular diseases...

(This article belongs to the Section Pharmacology)
  • Review
  • Open Access
41 Citations
6,590 Views
18 Pages

The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity

  • Victorita Sorodoc,
  • Oana Sirbu,
  • Catalina Lionte,
  • Raluca Ecaterina Haliga and ,
  • Alexandra Stoica,
  • Alexandr Ceasovschih,
  • Ovidiu Rusalim Petris,
  • Mihai Constantin,
  • Irina Iuliana Costache and
  • Laurentiu Sorodoc
  • + 7 authors+ 2 authors

3 August 2022

In cancer survivors, cardiac dysfunction is the main cause of mortality. Cardiotoxicity represents a decline in cardiac function associated with cancer therapy, and the risk factors include smoking, dyslipidemia, an age of over 60 years, obesity, and...

(This article belongs to the Special Issue Ischemic Heart Disease in the Context of Different Comorbidities)
  • Article
  • Open Access
7 Citations
3,263 Views
18 Pages

Limitations of Ferroptosis Inhibitors on the Doxorubicin-Induced Cardiotoxicity

  • Yun-Ji Cha,
  • Sae-Bom Jeon,
  • Chan Joo Lee,
  • Hyeong-Jin Kim and ,
  • Sun-Ho Lee,
  • Hyoeun Kim,
  • So Hee Park,
  • Elaine Zhelan Chen,
  • Jong Woo Kim and
  • Seunghyun Lee
  • + 9 authors+ 4 authors

24 December 2025

Doxorubicin is an anthracycline anticancer drug commonly used to treat lymphoma and breast cancer. Its major side effect is cardiotoxicity, which occurs by damaging cardiomyocytes. The mechanisms of doxorubicin-induced cardiotoxicity remain unclear;...

(This article belongs to the Special Issue Role of Oxidative Stress in Cardiac Remodeling and Heart Failure—3rd Edition)
  • Review
  • Open Access
6 Citations
2,995 Views
12 Pages

Due to the fact that statins are among the most high-demand therapeutic agents used for the treatment and prevention of the most common cardiovascular diseases, a significant amount of research is focused on these drugs. As a result, the study and di...

(This article belongs to the Section Cardiac Development and Regeneration)
  • Review
  • Open Access
826 Views
28 Pages

Apelin, Cortisol, and Doxorubicin-Induced Cardiotoxicity: A Triangle of Actions

  • Kinga Dziobiak,
  • Maja Owe-Larsson,
  • Mirosława Chwil and
  • Izabela Róża Janiuk

30 June 2026

The mechanisms underlying doxorubicin (DOX) cardiotoxicity include activation of the renin–angiotensin–aldosterone system (RAAS), oxidative stress, mitochondrial dysfunction, calcium overload, and cardiomyocyte apoptosis. Cortisol plays a...

  • Review
  • Open Access
40 Citations
8,384 Views
16 Pages

Pathophysiology of Doxorubicin-Mediated Cardiotoxicity

  • Roberto Arrigoni,
  • Emilio Jirillo and
  • Carlo Caiati

5 April 2025

Doxorubicin (DOX) is used for the treatment of various malignancies, including leukemias, lymphomas, sarcomas, and bladder, breast, and gynecological cancers in adults, adolescents, and children. However, DOX causes severe side effects in patients, s...

(This article belongs to the Special Issue Drug and Pesticides-Induced Oxidative Stress and Apoptosis)
  • Review
  • Open Access
40 Citations
6,121 Views
12 Pages

Doxorubicin (Dox) is one of the most frequently used chemotherapeutic drugs in a variety of cancers, but Dox-induced cardiotoxicity diminishes its therapeutic efficacy. The underlying mechanisms of Dox-induced cardiotoxicity are still not fully under...

(This article belongs to the Special Issue Molecular Toxicology and Cancer Prevention)
  • Article
  • Open Access
13 Citations
3,340 Views
21 Pages

Neutrophil Biomarkers Can Predict Cardiotoxicity of Anthracyclines in Breast Cancer

  • Valentina K. Todorova,
  • Gohar Azhar,
  • Annjanette Stone,
  • Sindhu J. Malapati and ,
  • Yingni Che,
  • Wei Zhang,
  • Issam Makhoul and
  • Jeanne Y. Wei
  • + 3 authors+ 0 author

9 September 2024

Doxorubicin (DOX), a commonly used anticancer agent, causes cardiotoxicity that begins with the first dose and may progress to heart failure years after treatment. An inflammatory response associated with neutrophil recruitment has been recognized as...

(This article belongs to the Special Issue Research Progress on the Mechanism and Treatment of Cardiomyopathy)
  • Review
  • Open Access
36 Citations
7,800 Views
22 Pages

Cardiotoxicity of Novel Targeted Hematological Therapies

  • Valentina Giudice,
  • Carmine Vecchione and
  • Carmine Selleri

11 December 2020

Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-related adverse events negatively affecting myocardial structure and functions in patients who received chemotherapy for cancer treatment. Clinical manifestati...

(This article belongs to the Special Issue New Molecules and Mechanisms to Fight the Onset and Progression Cardiovascular Diseases—the Role of Oxidative Stress)
  • Article
  • Open Access
36 Citations
1,890 Views
5 Pages

Capecitabine-Induced Cardiotoxicity: Case Report and Review of the Literature

  • C. Ang,
  • M. Kornbluth,
  • M. P. Thirlwell and
  • R. D. Rajan

1 February 2010

Capecitabine, an oral prodrug of 5-fluorouracil (5FU), has been integrated into the management of multiple cancer types because of convenience of administration and efficacy comparable with 5FU. Cardiotoxicity induced by 5FU—in particular angina—has...

  • Article
  • Open Access
3 Citations
1,706 Views
17 Pages

Using the Coefficient of Conformism of a Correlative Prediction in Simulation of Cardiotoxicity

  • Alla P. Toropova,
  • Andrey A. Toropov,
  • Alessandra Roncaglioni and
  • Emilio Benfenati

16 April 2025

The optimal descriptors generated by the CORAL software are studied as potential models of cardiotoxicity. Two significantly different cardiotoxicity databases are studied here. Database 1 contains 394 hERG inhibitors (pIC50) and external 200 substan...

  • Review
  • Open Access
10 Citations
7,794 Views
22 Pages

Cardiotoxicity in Breast Cancer Therapy: Risks, Mechanisms, and Prevention Strategies

  • Annisa Eka Fitrianti,
  • Nadea Olyvia Wardani,
  • Astri Astuti,
  • Kusnandar Anggadiredja and ,
  • Lia Amalia,
  • Risani Andalasia Putri and
  • Zulfan Zazuli
  • + 2 authors+ 0 author

14 August 2025

Breast cancer is the most prevalent cancer in women. Anthracyclines are commonly used as the first line of treatment, often combined with other agents, including trastuzumab. Despite their efficacy, both drugs pose a risk of cardiotoxicity, which may...

  • Communication
  • Open Access
26 Citations
9,037 Views
10 Pages

In Vivo Cardiotoxicity Induced by Sodium Aescinate in Zebrafish Larvae

  • Jinfeng Liang,
  • Wangdong Jin,
  • Hongwen Li,
  • Hongcui Liu and ,
  • Yanfeng Huang,
  • Xiaowen Shan,
  • Chunqi Li,
  • Letian Shan and
  • Thomas Efferth
  • + 4 authors+ 0 author

23 February 2016

Sodium aescinate (SA) is a widely-applied triterpene saponin product derived from horse chestnut seeds, possessing vasoactive and organ-protective activities with oral or injection administration in the clinic. To date, no toxicity or adverse events...

(This article belongs to the Section Natural Products Chemistry)
  • Review
  • Open Access
16 Citations
4,637 Views
20 Pages

Nutrition Modulation of Cardiotoxicity in Breast Cancer: A Scoping Review

  • Emma Stephenson,
  • Marie Mclaughlin,
  • James W. Bray,
  • John M. Saxton and
  • Rebecca V. Vince

3 November 2024

Background/Objectives: Advancements in breast cancer therapeutics, such as anthracyclines, are improving cancer survival rates but can have side effects that limit their use. Cardiotoxicity, defined as damage to the heart caused by cancer therapeutic...

(This article belongs to the Special Issue Nutrition, Physical Activity and Chronic Disease—2nd Edition)
  • Review
  • Open Access
22 Citations
6,947 Views
11 Pages

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents

  • Alexandros Briasoulis,
  • Angeliki Chasouraki,
  • Alexandros Sianis,
  • Nikolaos Panagiotou and ,
  • Christos Kourek,
  • Argyrios Ntalianis and
  • Ioannis Paraskevaidis
  • + 2 authors+ 0 author

Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer...

(This article belongs to the Special Issue Cardiovascular Toxicity Related to Cancer Treatment)
  • Article
  • Open Access
7 Citations
2,385 Views
9 Pages

Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib

  • Sidsel Pedersen,
  • Marc Østergaard Nielsen,
  • Marco Donia,
  • Inge Marie Svane and ,
  • Bo Zerahn and
  • Eva Ellebaek
  • + 1 author+ 0 author

23 August 2024

Modern therapies targeting the BRAF gene mutation in advanced melanoma have significantly improved patient outcomes but pose cardiovascular risks. This retrospective study in Eastern Denmark (2019–2022) assessed 108 melanoma patients treated wi...

(This article belongs to the Section Clinical Research in Cancer)
  • Article
  • Open Access
64 Citations
8,139 Views
11 Pages

Evaluation of the Cardiotoxicity of Evodiamine In Vitro and In Vivo

  • Weifeng Yang,
  • Lina Ma,
  • Sidi Li,
  • Kaiyu Cui and ,
  • Lei Lei and
  • Zuguang Ye
  • + 1 author+ 0 author

Evodiamine is a bioactive alkaloid that is specified as a biomarker for the quality assessment of Evodia rutaecarpa (E. rutaecarpa) and for traditional Chinese medicines containing this plant. We previously reported that quantitative structure–activi...

(This article belongs to the Collection Herbal Medicine Research)
  • Review
  • Open Access
27 Citations
9,055 Views
19 Pages

Mitochondria-Targeting Small Molecules Effectively Prevent Cardiotoxicity Induced by Doxorubicin

  • Wei Shi,
  • Hongkuan Deng,
  • Jianyong Zhang,
  • Ying Zhang and ,
  • Xiufang Zhang and
  • Guozhen Cui
  • + 1 author+ 0 author

Doxorubicin (Dox) is a chemotherapeutic agent widely used for the treatment of numerous cancers. However, the clinical use of Dox is limited by its unwanted cardiotoxicity. Mitochondrial dysfunction has been associated with Dox-induced cardiotoxicity...

(This article belongs to the Special Issue Recent Advances in Anticancer Drugs)
  • Review
  • Open Access
127 Citations
9,160 Views
20 Pages

Cardiotoxicity is the main side effect of several chemotherapeutic drugs. Doxorubicin (Doxo) is one of the most used anthracyclines in the treatment of many tumors, but the development of acute and chronic cardiotoxicity limits its clinical usefulnes...

(This article belongs to the Special Issue Molecular Pharmacology of Cardiovascular Disease, 2nd Edition)
  • Review
  • Open Access
12 Citations
5,521 Views
21 Pages

Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies

  • Anastasia Stella Perpinia,
  • Nikolaos Kadoglou,
  • Maria Vardaka,
  • Georgios Gkortzolidis and ,
  • Apostolos Karavidas,
  • Theodoros Marinakis,
  • Chrysostomi Papachrysostomou,
  • Panagiotis Makaronis,
  • Charikleia Vlachou and
  • Konstantinos Konstantopoulos
  • + 7 authors+ 2 authors

16 August 2022

Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, i...

(This article belongs to the Special Issue Drug Candidates for the Prevention and Treatment of Cardiovascular Diseases)
  • Article
  • Open Access
7 Citations
2,843 Views
13 Pages

Using the Correlation Intensity Index to Build a Model of Cardiotoxicity of Piperidine Derivatives

  • Alla P. Toropova,
  • Andrey A. Toropov,
  • Alessandra Roncaglioni and
  • Emilio Benfenati

12 September 2023

The assessment of cardiotoxicity is a persistent problem in medicinal chemistry. Quantitative structure–activity relationships (QSAR) are one possible way to build up models for cardiotoxicity. Here, we describe the results obtained with the Mo...

(This article belongs to the Section Computational and Theoretical Chemistry)
  • Review
  • Open Access
32 Citations
6,530 Views
22 Pages

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do

  • Concetta Zito,
  • Roberta Manganaro,
  • Giuliana Ciappina,
  • Calogera Claudia Spagnolo and ,
  • Vito Racanelli,
  • Mariacarmela Santarpia,
  • Nicola Silvestris and
  • Scipione Carerj
  • + 3 authors+ 0 author

2 November 2022

Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic scenario for several malignancies. However, they can be responsible for immune-related adverse events (irAEs), involving several organs, with a pooled incidence ranging between 5...

(This article belongs to the Special Issue Cancer Immunotherapy: Focus on Multidisciplinary Approaches and Predictive Biomarkers)
  • Review
  • Open Access
59 Citations
9,274 Views
15 Pages

Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review

  • Christos Kourek,
  • Maria Touloupaki,
  • Athanasios Rempakos,
  • Konstantinos Loritis and ,
  • Elias Tsougkos,
  • Ioannis Paraskevaidis and
  • Alexandros Briasoulis
  • + 2 authors+ 0 author

Cardiotoxicity is a significant complication of chemotherapeutic agents in cancer patients. Cardiovascular incidents including LV dysfunction, heart failure (HF), severe arrhythmias, arterial hypertension, and death are associated with high morbidity...

(This article belongs to the Special Issue Cardiovascular Toxicity Related to Cancer Treatment)
  • Systematic Review
  • Open Access
8 Citations
3,885 Views
14 Pages

Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis

  • Kyriakos Goulas,
  • Dimitrios Farmakis,
  • Anastasia Constantinidou and
  • Nikolaos P. E. Kadoglou

There are significant considerations about the prevention of cardiotoxicity caused by trastuzumab therapy in patients with breast cancer, leading to discontinuation. Recently, randomized controlled trials (RCTs) have evaluated the effects of early co...

(This article belongs to the Special Issue Drug Candidates for the Prevention and Treatment of Cardiovascular Diseases)
  • Review
  • Open Access
10 Citations
2,625 Views
26 Pages

Temporal Dynamics of Extracellular Matrix Remodeling in Anthracycline-Induced Cardiotoxicity

  • Fibi Meshrkey,
  • Somaya Y. Ibrahim,
  • Rushita A. Bagchi and
  • William J. Richardson

20 September 2025

Anthracyclines are widely used chemotherapeutic agents with proven efficacy against a broad range of malignancies, but their clinical utility is limited by a well-documented, dose-dependent cardiotoxicity. While this toxicity has traditionally been a...

(This article belongs to the Special Issue The Roles of the Extracellular Matrix in Cardiac Structure and Function: A Commemorative Issue in Honor of Dr. Thomas K. Borg)
  • Article
  • Open Access
10 Citations
4,276 Views
32 Pages

Small Extracellular Vesicles from Breast Cancer Cells Induce Cardiotoxicity

  • Jhon Jairo Osorio-Méndez,
  • Luis Alberto Gómez-Grosso,
  • Gladis Montoya-Ortiz,
  • Susana Novoa-Herrán and
  • Yohana Domínguez-Romero

Cardiovascular diseases and cancer are leading global causes of morbidity and mortality, necessitating advances in diagnosis and treatment. Doxorubicin (Doxo), a potent chemotherapy drug, causes long-term heart damage due to cardiotoxicity. Small ext...

(This article belongs to the Special Issue Exosomes and Non-Coding RNA Research in Health and Disease)
  • Article
  • Open Access
25 Citations
5,344 Views
17 Pages

Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion

  • Gábor B. Brenner,
  • András Makkos,
  • Csilla Terézia Nagy,
  • Zsófia Onódi and ,
  • Nabil V. Sayour,
  • Tamás G. Gergely,
  • Bernadett Kiss,
  • Anikó Görbe,
  • Éva Sághy and
  • Péter Ferdinandy
  • + 15 authors+ 10 authors

26 February 2020

Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is defined as cardiotoxicity of a drug that manifests...

  • Systematic Review
  • Open Access
1 Citations
2,198 Views
24 Pages

Machine Learning for Predicting Human Drug-Induced Cardiotoxicity: A Scoping Review

  • Ja-Young Han,
  • Min Jung Kim,
  • Hyunwoo Kim,
  • KeunOh Choi and ,
  • Seongjin Ju and
  • Myeong Gyu Kim
  • + 1 author+ 0 author

17 December 2025

Background: Drug-induced cardiotoxicity poses a major challenge in drug development and clinical safety. Although machine learning (ML) methods have shown potential in predicting cardiotoxic risks, prior research has largely focused on specific mecha...

(This article belongs to the Section Drugs Toxicity)
  • Article
  • Open Access
8 Citations
2,498 Views
10 Pages

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data

  • Irene Toribio-García,
  • Alejandro Olivares-Hernández,
  • José Pablo Miramontes-González,
  • Luis Posado-Domínguez and ,
  • Ana Martín García,
  • Rocío Eiros Bachiller,
  • Luis Figuero-Pérez,
  • María Garijo Martínez,
  • Jonnathan Roldán Ruiz and
  • Edel del Barco-Morillo
  • + 8 authors+ 3 authors

28 August 2023

Introduction: Immunotherapy represents a key pillar of cancer treatments, with high response rates and long survival. Its use is increasing, mainly at the expense of the geriatric population due to the ageing of this population. However, despite its...

(This article belongs to the Special Issue Targeting Solid Tumors and the Microenvironment with Novel Immunotherapies)
  • Review
  • Open Access
25 Citations
9,060 Views
36 Pages

Recent Advances in Mitochondrial Fission/Fusion-Targeted Therapy in Doxorubicin-Induced Cardiotoxicity

  • Chayodom Maneechote,
  • Siriporn C. Chattipakorn and
  • Nipon Chattipakorn

Doxorubicin (DOX) has been recognized as one of the most effective chemotherapies and extensively used in the clinical settings of human cancer. However, DOX-mediated cardiotoxicity is known to compromise the clinical effectiveness of chemotherapy, r...

(This article belongs to the Special Issue Advances in Mitochondria-Targeted Drug Delivery)
  • Opinion
  • Open Access
16 Citations
5,810 Views
40 Pages

Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice

  • Giuliana Ciappina,
  • Luigi Colarusso,
  • Enrica Maiorana,
  • Alessandro Ottaiano and ,
  • Tindara Franchina,
  • Antonio Picone,
  • Gaetano Facchini,
  • Chiara Barraco,
  • Antonio Ieni and
  • Massimiliano Berretta
  • + 7 authors+ 2 authors

17 September 2025

The introduction of novel oncologic therapies, including targeted agents, immunotherapies, and antibody–drug conjugates, has transformed the therapeutic landscape of cancer care. This evolution has resulted in a dual clinical scenario; while su...

(This article belongs to the Special Issue Emerging Therapeutics for the Prevention of Chemotherapy-Induced Cardiotoxicity: Advances and Future Perspectives)
  • Review
  • Open Access
11 Citations
3,524 Views
27 Pages

Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies

  • Kondylia Antoniadi,
  • Nikolaos Thomaidis,
  • Petros Nihoyannopoulos,
  • Konstantinos Toutouzas and ,
  • Evangelos Gikas,
  • Charikleia Kelaidi and
  • Sophia Polychronopoulou
  • + 2 authors+ 0 author

Improvements in the treatment of childhood cancer have considerably enhanced survival rates over the last decades to over 80% as of today. However, this great achievement has been accompanied by the occurrence of several early and long-term treatment...

(This article belongs to the Special Issue Prognostic Factors for Pediatric Tumors)
  • Article
  • Open Access
4 Citations
2,165 Views
11 Pages

Serum Albumin–Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with Cancer

  • Onur Baş,
  • Naciye Güdük,
  • Mert Tokatlı,
  • Deniz Can Güven and ,
  • Necla Özer,
  • Yusuf Ziya Şener,
  • Serkan Akın,
  • Sercan Aksoy,
  • İbrahim Barışta and
  • Ömer Dizdar
  • + 6 authors+ 1 author

5 March 2025

Background: Several studies have suggested that the serum albumin–creatinine ratio (sACR) is a useful marker for the early risk stratification of patients with cardiomyocyte injury. This study aims to evaluate the relationship between sACR and...

(This article belongs to the Section Oncology)
  • Review
  • Open Access
18 Citations
5,703 Views
24 Pages

Natural Products for Preventing and Managing Anthracycline-Induced Cardiotoxicity: A Comprehensive Review

  • Jarosław Szponar,
  • Przemysław Niziński,
  • Jarosław Dudka,
  • Kamila Kasprzak-Drozd and
  • Anna Oniszczuk

6 July 2024

Doxorubicin (DOX) is an anthracycline anticancer agent that is highly effective in the treatment of solid tumors. Given the multiplicity of mechanisms involved in doxorubicin-induced cardiotoxicity, it is difficult to identify a precise molecular tar...

  • Article
  • Open Access
13 Citations
3,860 Views
11 Pages

ECG Scoring for the Evaluation of Therapy-Naïve Cancer Patients to Predict Cardiotoxicity

  • Julia Pohl,
  • Raluca-Ileana Mincu,
  • Simone M. Mrotzek,
  • Reza Wakili and ,
  • Amir A. Mahabadi,
  • Sophia K. Potthoff,
  • Jens T. Siveke,
  • Ulrich Keller,
  • Ulf Landmesser and
  • Matthias Totzeck
  • + 7 authors+ 2 authors

10 March 2021

Objective: To evaluate a new electrocardiographic (ECG) score reflecting domains of electrical and structural alterations in therapy-naïve cancer patients to assess their risk of cardiotoxicity. Methods: We performed a retrospective analysis of 134 t...

  • Article
  • Open Access
7 Citations
3,019 Views
18 Pages

Cardiotoxicity in Breast Cancer: Impact of Clinical Classifications and Treatment on Heart Health

  • Sergiu Ioan Murg,
  • Loredana Matiș,
  • Andrada Florina Moldovan,
  • Andrada Florina Schwarz-Madar and ,
  • Daniela Florina Trifan,
  • Timea Claudia Ghitea and
  • Mircea Ioachim Popescu
  • + 2 authors+ 0 author

23 December 2024

Background/Objectives: Cardio-oncology has become essential in addressing cardiovascular complications from cancer therapies. While advancements in treatments have improved survival rates, they also increase cardiovascular risks. This study evaluates...

(This article belongs to the Section Clinical Research in Cancer)

of 27